Mark Ratain to Drug Labeling
This is a "connection" page, showing publications Mark Ratain has written about Drug Labeling.
Connection Strength
2.782
-
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority. Clin Transl Sci. 2025 Sep; 18(9):e70337.
Score: 0.922
-
Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8.
Score: 0.428
-
Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
Score: 0.401
-
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 01; 16(17):4446-51.
Score: 0.325
-
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol. 2002 Mar 15; 20(6):1434-5.
Score: 0.181
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.130
-
Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612.
Score: 0.128
-
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29.
Score: 0.113
-
Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011 Oct 20; 29(30):3958-9.
Score: 0.088
-
The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8.
Score: 0.066